FDA clears Theradaptive’s OASIS pivotal trial as spinal fusion graft race enters a new phase
Spine biologics has long lacked fresh competition. Theradaptive’s OsteoAdapt SP trial could test whether that market is ready to move.
Why Theradaptive’s OsteoAdapt could disrupt the $2bn spinal biologics market in 2026
ATEC secures U.S. rights to Theradaptive’s OsteoAdapt. Find out what this deal changes for spinal biologics in 2026 and beyond.